TNF Inhibitor denied as experimental or investigational by Highmark?

Highmark uses Prime Therapeutics PBM. Adalimumab biosimilar preferred (Cyltezo/Hyrimoz/Yusimry). Step therapy through preferred biosimilar required for new starts; existing patients on Humira may grandfather.

Highmark Continuity of Care provisions — 90-day grandfather for established therapy. Cite Prime Therapeutics PA exception process. ACR 2019 Position Statement opposes non-medical switching of stable patients.

## Why Highmark May Deny a TNF Inhibitor as "Experimental or Investigational"

TNF inhibitors have been FDA-approved for multiple indications for many years and are among the most thoroughly studied biologics in clinical medicine. An "experimental or investigational" denial from Highmark in this context almost always means one of the following: (1) the drug is being prescribed for an indication not listed in its FDA-approved label; (2) the specific formulation or route of administration is not approved; or (3) Highmark's medical policy for this indication has not been updated to reflect recent approvals or clinical consensus.

## Why This Denial Is Often Appealable

For any FDA-approved indication, a characterization of "experimental" is factually incorrect and is a strong basis for appeal. The FDA approval itself is the primary rebuttal. Even for off-label uses, many state insurance laws and plan documents require coverage when substantial clinical evidence supports the use, and Pennsylvania's insurance code (applicable to Highmark's in-state plans) has provisions supporting coverage of evidence-based off-label oncology and certain other uses. The key is to document the evidentiary basis — specialist consensus, professional-society guidance, peer-reviewed support — without relying on specific numeric claims.

## Your Federal Appeal Rights

• Internal appeal: Submit within the timeframe on your denial notice. Highmark must decide pre-service non-urgent appeals within 30 days; post-service within 60 days.
• External review (ACA §2719): After a final internal denial, request IRO external review within approximately four months. Experimental/investigational denials are among the most commonly overturned categories at external review. The IRO decision binds Highmark.
• Expedited review: If delay would seriously harm your health, request expedited review for a decision typically within 72 hours.
• ERISA §503: Employer-plan members may review all documents used in the denial and submit evidence on their own behalf.

## Documentation to Gather

1. FDA-approved prescribing information — the current full label showing the approved indications. If your indication is listed, this is your central exhibit. 2. Highmark's experimental/investigational policy — obtain the current version of Highmark's medical policy for the drug and for the "experimental" classification standard so you can respond to each criterion. 3. Relevant professional-society position statements — guidance from organizations such as the American College of Rheumatology, American Gastroenterological Association, or American Academy of Dermatology supporting use of this drug class for your diagnosis. 4. Prescriber medical-necessity letter — a detailed letter from the treating specialist explaining the diagnosis, the evidence basis for prescribing this TNF inhibitor, and why it is the standard of care for this patient. 5. Clinical records — chart notes documenting disease severity, prior treatments, and the clinical rationale for this therapy.

## Criteria-Mapping Strategy

Obtain Highmark's definition of "experimental" as stated in their medical policy (typically requiring that a treatment lack sufficient clinical evidence or regulatory approval). Map each element of that definition to the contrary evidence: FDA approval status, professional-society endorsement, and the prescriber's clinical rationale. If the denial was based on an outdated policy, note the discrepancy between the policy date and the FDA approval date and request that Highmark apply its most current policy.